Previous 10 | Next 10 |
On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid. Vozxogo remains the main driver of revenue growth this year. If approved in Europe, the start...
A committee of the European Medicines Agency (EMA) recommended conditional marketing authorization of BioMarin Pharmaceutical's (NASDAQ:BMRN) gene therapy Roctavian to treat severe hemophilia A. The EMA's Committee for Medicinal Products for Human Use said Roctavian (valoctocogene r...
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A PR Newswire European Commission Approval Expected Q3 2022 1st Gene Therapy for Treatment of Hemophilia A Recommended for Appro...
3 Pharmaceutical Stocks For Your Watchlist Right Now For investors wondering what are the best stocks to invest in today, pharmaceutical stocks would be an interesting play. On the whole, this part of the stock market is home to companies of varying sizes and specializations...
BioMarin Pharmaceutical (NASDAQ:BMRN) said Tuesday Japan's Ministry of Health, Labor and Welfare (MHLW) granted approval of registration of Voxzogo for injection to treat achondroplasia in children of all ages. Voxzogo is a modified C-type natriuretic peptide that directly targets the un...
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed PR Newswire No Lower Age Restriction for Tre...
Wedbush Securities has initiated Sangamo Therapeutics (NASDAQ:SGMO) with a hold rating noting that while it sees promise in isaralgagene civaparvovec for Fabry disease, the candidate needs to demonstrate better durable efficacy and safety compared to current treatments. The firm has a $5 pric...
Wedbush Securities has initiated BioMarin Pharmaceutical (NASDAQ:BMRN) with a neutral rating saying that the launch of Voxsogo (vosoritide) for achondroplasia and potential approval of Roctavian (valoctocogene roxaparvovec) for hemophilia are key to the biotech's growth. The firm has a $70 pr...
Announcing data from a Phase 2 trial, the commercial-stage biotech BioMarin Pharmaceutical (NASDAQ:BMRN) announced Monday it would seek labeling expansion for the use of achondroplasia therapy Voxzogo in younger children. Voxzogo is currently indicated in the U.S. for pediatric patients with ...
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta PR Newswire Improvement in Height Z-...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...